Public release date: 13-Nov-2012 [ | E-mail | Share ] Contact: Joan Robinson joan.robinson@springer.com 49-622-148-78130 Springer Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism. Their work is published online in Springer's Journal of Medical Toxicology. Metal-binding agents such as DMPS* have received significant attention in recent decades amid the controversy over the link between mercury and autism. Even though no causal relationship between mercury in vaccines and autism has been proven, some practitioners treat their patients with mercury-binding agents in an effort to help the body eliminate mercury and treat the autism. One of these agents is a formulation of DMPS which is applied to the skin, also known as topical application. DMPS is approved in Europe for the treatment of heavy metal toxicity, but is not approved by the US FDA for use in the USA. For the first time, Cohen and … Continue reading →

ScienceDaily (Nov. 13, 2012) Metal-binding agents rubbed into the skin, prescribed by some alternative practitioners for the treatment of autism, are not absorbed and therefore are unlikely to be effective at helping the body excrete excess mercury, a new study finds. The study by Jennifer Cohen and Michelle Ruha from Banner Good Samaritan Medical Center in the US, and their colleagues, provides evidence against the use of these treatments in children with autism. Their work is published online in Springer's Journal of Medical Toxicology. Metal-binding agents such as DMPS (2,3-Dimercaptopropane-1-sulfonate) have received significant attention in recent decades amid the controversy over the link between mercury and autism. Even though no causal relationship between mercury in vaccines and autism has been proven, some practitioners treat their patients with mercury-binding agents in an effort to help the body eliminate mercury and treat the autism. One of these agents is a formulation of DMPS which is applied to the skin, also known as topical application. DMPS is approved in Europe for the treatment of heavy metal toxicity, but is not approved by the US FDA for use in the USA. For the first time, Cohen and team looked at whether topically applied DMPS … Continue reading →

Methodist Sugar Land Hospital has received the American Heart Association/American Stroke Associations Get With The Guidelines-Stroke Gold Plus Quality Achievement Award. The award recognizes Methodist Sugar Land Hospitals commitment and success in implementing a higher standard of stroke care by ensuring that stroke patients receive treatment according to nationally accepted standards and recommendations. With a stroke, time lost is brain lost, and the Get With The GuidelinesStroke Gold Plus Quality Achievement Award demonstrates Methodist Sugar Land Hospitals commitment to being one of the top hospitals in the country for providing aggressive, proven stroke care and addressing the important element of time, said James Ling, M.D., Medical Director of the Methodist Sugar Land Stroke Program. We will continue with our focus on providing care that has been shown in the scientific literature to quickly and efficiently treat stroke patients with evidence-based protocols, said Maria Socci, Manager, Stroke Program. Methodist Sugar Land Hospital has developed a comprehensive system for rapid diagnosis and treatment of stroke patients admitted to the emergency department. This includes always being equipped to provide brain imaging scans, having neurologists available to conduct patient evaluations and using clot-busting medications when appropriate. To receive the award, Methodist Sugar Land Hospital … Continue reading →